The study of Livergol® effect on rheumatoid arthritis patients
Not Applicable
- Conditions
- rheumatoid arthritis.Seropositive rheumatoid arthritis
- Registration Number
- IRCT2013121915870N1
- Lead Sponsor
- Vice Chancellor for research of Kermanshah University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
having four of the seven criteria, of American College of Rheumatology for six weeks and Diagnosis by a Rheumatologist
Exclusion criteria: Patients participating in the study will be free to withdraw from the study.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Interleukin 1. Timepoint: before and after advising the drug. Method of measurement: ELISA.;TNF-a. Timepoint: before and after advising the drug. Method of measurement: ELISA.;Neopterin. Timepoint: before and after advising the drug. Method of measurement: HPLC.;Malondialdehyde. Timepoint: before and after advising the drug. Method of measurement: HPLC.;Catalase. Timepoint: before and after advising the drug. Method of measurement: spectrophotometry system.;Paraoxonase. Timepoint: before and after advising the drug. Method of measurement: spectrophotometry system.
- Secondary Outcome Measures
Name Time Method ESR. Timepoint: before and after the drug. Method of measurement: westregreen.;CRP. Timepoint: before and after the drug. Method of measurement: ELISA.;Mmp-2. Timepoint: before and after the drug. Method of measurement: ELISA and gelatin zymography.;Mmp-9. Timepoint: before and after the drug. Method of measurement: ELISA and gelatin zymography.